Iovance Biotherapeutics, Inc. (0JDK.L) LSE

Currency In USD

Key Executives

Name	Title	Pay	Year Born
Frederick G. Vogt	Interim Chief Executive Officer, President, General Counsel, Corporate Secretary & Director	1.13M	1974
Elma S. Hawkins	Advisor to the Board	465,395	1957
Corleen Roche	Chief Financial Officer	494,150	1966
Igor Bilinsky	Chief Operating Officer	738,374	1973
Friedrich Graf Finckenstein	Chief Medical Officer	764,634	1967
Daniel G. Kirby	Chief Commercial Officer	804,031	1972
Raj K. Puri	Chief Regulatory Officer	867,158	1956
Brian Gastman	Executive Vice President of Medical Affairs	0	N/A
Brian Shew	Senior Vice President & Head of Digital and Information Technology	0	N/A
Matthew W. Rosinack	Principal Accounting Officer	0	1972
Howard Johnson	Chief Business Officer	0	1960
Kevin Smyth	Executive Vice President of Quality	0	N/A
Tracy Winton	Executive Vice President of Human Resources	0	N/A
Marc R. Theoret	Senior Vice President of Regulatory Strategy	0	N/A
Sara Pellegrino	Senior Vice President of Investor Relations & Corporate Communications	0	N/A

Name

Title

Pay

Year Born

Frederick G. Vogt

Interim Chief Executive Officer, President, General Counsel, Corporate Secretary & Director

1.13M

1974

Elma S. Hawkins

Advisor to the Board

465,395

1957

Corleen Roche

Chief Financial Officer

494,150

1966

Igor Bilinsky

Chief Operating Officer

738,374

1973

Friedrich Graf Finckenstein

Chief Medical Officer

764,634

1967

Daniel G. Kirby

Chief Commercial Officer

804,031

1972

Raj K. Puri

Chief Regulatory Officer

867,158

1956

Brian Gastman

Executive Vice President of Medical Affairs

N/A

Brian Shew

Senior Vice President & Head of Digital and Information Technology

N/A

Matthew W. Rosinack

Principal Accounting Officer

1972

Howard Johnson

Chief Business Officer

1960

Kevin Smyth

Executive Vice President of Quality

N/A

Tracy Winton

Executive Vice President of Human Resources

N/A

Marc R. Theoret

Senior Vice President of Regulatory Strategy

N/A

Sara Pellegrino

Senior Vice President of Investor Relations & Corporate Communications

N/A

Description

Iovance Biotherapeutics, Inc. is a clinical-stage biotechnology firm committed to advancing and bringing to market innovative cancer immunotherapies. Its fundamental objective is to leverage and direct a patient's own immune system to identify and eradicate cancerous cells. The company currently oversees six ongoing Phase 2 clinical trials. Notably, its primary therapeutic candidate, lifileucel, is under investigation in two of these studies: C-144-01 for advanced melanoma and C-145-04 for cervical cancer that is recurrent, metastatic, or persistent. Furthermore, another candidate, LN-145, is being assessed in study C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics maintains strategic alliances and licensing arrangements with esteemed institutions including H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Incorporated in 2007 and situated in San Carlos, California, the organization was formerly known as Lion Biotechnologies, Inc. until its rebranding in June 2017.